• 湿润烧伤膏联合酮替芬治疗面部皮炎的临床疗效观察
  • Clinical Efficacy Observation of Moist Exposed Burn Ointment Combined with Ketotifen in the Treatment of Facial Dermatitis
  • 王新平.湿润烧伤膏联合酮替芬治疗面部皮炎的临床疗效观察[J].中国烧伤创疡杂志,2015,(6):445~448.
    DOI:
    中文关键词:  湿润烧伤膏  皮炎  面部  酮替芬  疗效
    英文关键词:Moist Exposed Burn Ointment  Dermatitis  Face  Ketotifen  Efficacy
    基金项目:
    作者单位
    王新平 利津县第二人民医院外科 
    摘要点击次数: 2368
    全文下载次数: 4391
    中文摘要:
          目的 观察湿润平均治愈时间为9.13d ±3.04d, 显著低于对照组的15.9d ±4.87d (t=4.836, P<0.01), 差异具有统计学意义?治疗第3天, 两组患者的痊愈率及总有效率对比, 差异均无统计学意义(P>0.05);治疗第7天, 两组患者的痊愈率及总有效率对比, 差异均有统计学意义(P<0.01);治疗第10天, 两组患者的痊愈率及总有效率对烧伤膏(Moist Exposed Burn Ointment, MEBO) 联合酮替芬治疗面部皮炎的临床疗效?方法 将56例面部皮炎患者随机分为观察组与对照组, 观察组给予外用MEBO 联合口服酮替芬治疗, 对照组仅给予口服酮替芬治疗?治疗前及治疗后3?7?10d各随访1次, 观察两组临床疗效? 结果 观察组患者的比, 差异均有统计学意义(P<0.01)? 结论 湿润烧伤膏联合酮替芬治疗面部皮炎疗效显著, 操作简便, 且安全有效, 值得临床推广应用?
    英文摘要:
          Objective To observe the clinical efficacy of Moist Exposed Burn Ointment (MEBO) combined with Ketotifen in the treatment of facial dermatitis. Methods 56 patients with facial dermatitis were randomly divided into an observation group and a control group. MEBO combined with oral Ketotifen was given in the observation group while only oral Ketotifen was given in the control group. Follow-up was conducted respectively before the treatment and on day 3, day 7, day 10 after the treatment to observe the clinical efficacy. Results the mean healing time in the observation group was 9.13 d±3.04 d, obviously being shorter than 15.9 d±4.87 d in the control group (t=4.836, P<0.01). on day 3 after the treatment, there was no statistically significant difference between the two groups in terms of cure rate and total effective rate (P>0.05). On day 7 and day 10 after the treatment, there were statistically significant differences between the two groups in terms of cure rate and total effective rate respectively (P<0.01). Conclusion With its faster wound healing, easy operation and efficient safety, MEBO combined with Ketotifen can realize significant clinical efficacy in treating facial dermatitis, meriting clinical promotion and application.